Tags : Fascioliasis

Novartis’ Egaten (triclabendazole) Receives FDA’s Approval for Fascioliasis in the

Vartika Singh February 14, 2019

Shots: The approval is based on the study assessing Egaten (triclabendazole) in patients with fascioliasis aged ≥ 6yrs. Novartis’ Egaten is in use since 2005 by WH, serving 2M fascioliasis […]readmore

Tags : Fascioliasis

Novartis’ Egaten (triclabendazole) Receives FDA’s Approval for Fascioliasis in the

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : Fascioliasis

Novartis’ Egaten (triclabendazole) Receives FDA’s Approval for Fascioliasis in the

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company